VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2021 | Abemaciclib for HR+/HER2- advanced or metastatic breast cancer

Ahmad Awada, MD, PhD, Institute Jules Bordet, Brussels, Belgium, talks on the use of abemaciclib, a CDK 4/6 inhibitor, for the treatment of HR+/HER2- advanced or metastatic breast cancer, highlighting results from the MONARCH 2 trial (NCT02107703). This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Disclosures

Ahmad Awada, MD, PhD, has participated in an advisory role, has received institutional research grants, or has received speakers fees from Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck and Daiichi.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter